Cancer Research Aziza Shad  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 69, 5301, July 1, 2009. Published Online First June 23, 2009;
doi: 10.1158/0008-5472.CAN-09-0884
© 2009 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
0008-5472.CAN-09-0884v1
69/13/5301    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Horvath, A.
Right arrow Articles by Stratakis, C. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Horvath, A.
Right arrow Articles by Stratakis, C. A.

Priority Reports

Functional Phosphodiesterase 11A Mutations May Modify the Risk of Familial and Bilateral Testicular Germ Cell Tumors

Anelia Horvath1, Larissa Korde2, Mark H. Greene2, Rossella Libe5, Paulo Osorio1,7, Fabio Rueda Faucz1,7, Marie Laure Raffin-Sanson6,8,9, Kit Man Tsang1, Limor Drori-Herishanu1, Yianna Patronas1, Elaine F. Remmers4, Maria Eleni Nikita1, Jason Moran1, Joseph Greene1, Maria Nesterova1, Maria Merino3, Jerome Bertherat5 and Constantine A. Stratakis1

1 Program on Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development; 2 Clinical Genetics Branch and 3 Laboratory of Pathology, National Cancer Institute; and 4 Genetics and Genomics Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland; 5 Institut National de la Sante et de la Recherche Medicale U567, and Institut Cochin, Centre National de la Recherche Scientifique UMR8104, Hôpital Cochin, Université Paris Descartes; 6 Institut National de la Sante et de la Recherche Medicale U567, Departement Endocrinologie, Metabolisme and Cancer, Institut Cochin, and Centre National de la Recherche Scientifique UMR8104, Paris, France; 7 Laboratory of Molecular Genetics, Pontificia Universidade Catolica do Parana, Curitiba, Brazil; 8 Hôpital Ambroise Paré, Department of Endocrinology, Boulogne sur Seine, France; and 9 Université de Versailles, St. Quentin en Yvelines, France

Requests for reprints: Anelia Horvath, Program on Developmental Endocrinology and Genetics (PDEGEN), Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 10 Center Drive, CRC, Room 1-3330, Bethesda, MD 20892. Phone: 301-402-1998; Fax: 301-402-0574; E-mail: horvatha{at}mail.nih.gov.

Key Words: Phosphodiesterase (PDE) • testicular cancer • TGCT • mutations • cAMP

Inactivating germline mutations in phosphodiesterase 11A (PDE11A) have been implicated in adrenal tumor susceptibility. PDE11A is highly expressed in endocrine steroidogenic tissues, especially the testis, and mice with inactivated Pde11a exhibit male infertility, a known testicular germ cell tumor (TGCT) risk factor. We sequenced the PDE11A gene-coding region in 95 patients with TGCT from 64 unrelated kindreds. We identified 8 nonsynonymous substitutions in 20 patients from 15 families: four (R52T, F258Y, G291R, and V820M) were newly recognized, three (R804H, R867G, and M878V) were functional variants previously implicated in adrenal tumor predisposition, and one (Y727C) was a known polymorphism. We compared the frequency of these variants in our patients to unrelated controls that had been screened and found negative for any endocrine diseases: only the two previously reported variants, R804H and R867G, known to be frequent in general population, were detected in these controls. The frequency of all PDE11A-gene variants (combined) was significantly higher among patients with TGCT (P = 0.0002), present in 19% of the families of our cohort. Most variants were detected in the general population, but functional studies showed that all these mutations reduced PDE activity, and that PDE11A protein expression was decreased (or absent) in TGCT samples from carriers. This is the first demonstration of the involvement of a PDE gene in TGCT, although the cyclic AMP signaling pathway has been investigated extensively in reproductive organ function and their diseases. In conclusion, we report that PDE11A-inactivating sequence variants may modify the risk of familial and bilateral TGCT. [Cancer Res 2009;69(13):5301–6]




This article has been cited by other articles:


Home page
Eur J EndocrinolHome page
E Peverelli, F Ermetici, M Filopanti, F M Elli, C L Ronchi, G Mantovani, S Ferrero, S Bosari, P Beck-Peccoz, A Lania, et al.
Analysis of genetic variants of phosphodiesterase 11A in acromegalic patients
Eur. J. Endocrinol., November 1, 2009; 161(5): 687 - 694.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2009 by the American Association for Cancer Research.